Adagene Inc.
NASDAQ:ADAGBiotechnology
+$0.13 today
- Market cap
- $68.52M
- Beta
- 0.59
- P/E (TTM)
- -7.9
- EPS (TTM)
- -$0.47
Volume 1.30M
Average 0.21M
ADAG Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Adagene Inc.NASDAQ: ADAG
Depreciation & Amortization · Q4 FY2025 · quarter ended Dec 2025
Depreciation & amortization dips below year-ago levels
Q4 FY2025 depreciation & amortization of $282.32K fell 57.8% year over year, behind the +2393.6% change in trailing-twelve-month depreciation & amortization. Over 3 fiscal years it compounded at -25.9% a year.
Context
- Depreciation & amortization amounted to 7.7% of revenue in FY2025, down 889.8 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -57.8% toward the trailing-twelve-month pace of +2393.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 589.79K USD
- Year-over-year change
- -36.3%
- 4-year CAGR
- -14.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 589.79K | -36.3% |
| FY2024 | 2024-12-31 | 926.25K | -23.4% |
| FY2023 | 2023-12-31 | 1.21M | -16.6% |
| FY2022 | 2022-12-31 | 1.45M | +28.8% |
| FY2021 | 2021-12-31 | 1.13M | — |
Depreciation & Amortization vs competitors
How ADAG compares with its peers on the latest reported figures
- ADAG's LTM Jun 2024 depreciation & amortization of $515.94K is the 6th largest of the 9 companies compared; the peer median is $2.23M.
- Depreciation & amortization amounts to 63.2% of revenue for ADAG, versus a peer median of 11.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $363.33M | +106428.1% | +7569.0% | — |
| LTM Mar 2026 | $5.17M | +4.4% | -20.7% | 7.8% | |
| LTM Mar 2026 | $3.86M | -37.8% | -3.9% | — | |
| LTM Mar 2026 | $2.88M | -18.4% | -17.7% | 31.5% | |
| LTM Mar 2026 | $1.58M | -10.2% | -13.6% | — | |
| LTM Jun 2024 | $515.94K | — | -25.9% | 63.2% | |
| LTM Mar 2026 | $305K | +6000.0% | +229.4% | 13.3% | |
| LTM Apr 2026 | $170.49K | -37.6% | -19.3% | 9.5% | |
| LTM Mar 2026 | $94.69K | +12.5% | +13.6% | — | |
| Peer median (excluding ADAG) | $2.23M | -2.9% | -8.7% | 11.4% | |
Competitors are the stored peer set for ADAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (73.18M) | (79.97M) | (18.95M) | (33.42M) | (17.61M) |
| Depreciation & Amortization | 1.13M | 1.45M | 1.21M | 926.25K | 589.79K |
| Deferred Income Tax | 622.43K | (44.16K) | 0 | 0 | 0 |
| Stock-Based Compensation | 18.68M | 10.52M | 7.27M | 4.91M | 3.74M |
| Change in Working Capital | 9.35M | 21.94M | (16.55M) | (1.89M) | (775.3K) |
| Accounts Receivables | (3M) | 6.89M | 397.41K | 213.72K | (9.04K) |
| Inventory | 6.02M | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.51M | 344.51K | (572.37K) | 1.15M | (1.36M) |
| Other Working Capital | 4.82M | 14.75M | (16.38M) | (3.25M) | 591.01K |
| Other Non-Cash Items | (9.95K) | (2.5M) | (1.44M) | (222.24K) | (1.6M) |
| Operating Cash Flow | (43.41M) | (48.61M) | (28.45M) | (29.7M) | (15.66M) |
| Capital Expenditures | (2.51M) | (690.94K) | (85.01K) | (33.58K) | (17.05K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (47M) | (128.5M) | (80M) |
| Sales of Investments | 0 | 0 | 47M | 129.64M | 80.49M |
| Other Investing Activities | 0 | 4.89K | 7.66K | 169 | 1.4K |
| Investing Cash Flow | (2.51M) | (686.05K) | (77.36K) | 1.11M | 476.8K |
| Debt Repayment | (702.86K) | 21.48M | (5.37M) | (3.42M) | (12.24M) |
| Common Stock Issued | 149.79M | 0 | 5.5K | 7.33M | 138.28K |
| Common Stock Repurchased | (2.36M) | (3.98M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.37M) | 323.21K | 5.5K | (137.3K) | 0 |
| Financing Cash Flow | 145.36M | 17.82M | (5.37M) | 3.77M | 4.45M |
| Effect of Forex Changes | (192.35K) | 842.2K | 74.72K | 81.88K | 64.55K |
| Net Change in Cash | 99.24M | (30.63M) | (33.82M) | (24.74M) | (10.67M) |
| Free Cash Flow | (45.92M) | (49.3M) | (28.54M) | (29.73M) | (15.67M) |
Adagene Inc.
NASDAQ:ADAG
Intrinsic Alpha fair value
Locked
Current Price
$1.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.